| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/18/2006 | WO2006051410A1 Azabenzoxazoles for the treatment of cns disorders |
| 05/18/2006 | WO2006050999A2 Methods of reducing body fat |
| 05/18/2006 | WO2006050975A1 Nutrition containing fat blend |
| 05/18/2006 | WO2006050842A1 Dibenzosuberone derivatives |
| 05/18/2006 | WO2006034341A3 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| 05/18/2006 | WO2006020091A3 Dietary supplements containing extracts of cinnamon and methods of using same to promote weight loss |
| 05/18/2006 | WO2006015297A3 Methods of treating type i diabetes by blocking vegf-mediated activity |
| 05/18/2006 | WO2006007818A3 Method for systemic bio-correction of an organism |
| 05/18/2006 | US20060106232 atorvastatin hemi-calcium Form X and solvates of given powder X-ray diffraction pattern; small particle size distribution; dosage forms |
| 05/18/2006 | US20060106231 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 05/18/2006 | US20060106228 Process for preparing 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl) ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
| 05/18/2006 | US20060106202 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use |
| 05/18/2006 | US20060106111 Phenylnaphthalene compounds |
| 05/18/2006 | US20060106087 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative |
| 05/18/2006 | US20060106082 N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenylsulfonyl]-4-nitrooxybutanamide, used for the treatment of inflammatory, cardiovascular, gastrointestinal, respiratory and nervous system disorders, as analgesics, antipyretics and antocoagulants or for organ and tissue preservation |
| 05/18/2006 | US20060106072 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
| 05/18/2006 | US20060106059 Melanocortin receptor ligands |
| 05/18/2006 | US20060106048 Furoisoquinoline derivative and use thereof |
| 05/18/2006 | US20060106046 2-(3,4-difluorophenyl)-N-methyl-2-(1H-1,2,3-triazol-1-yl)-N-[3-(spiro[isobenzofuran-1(3H), 4'-piperidin]-1-yl)propyl]acetamide, used for preventing or treating cardiovascular, nervous, metabolic, reproductive, respiratory and/or digestive system disorders |
| 05/18/2006 | US20060106008 Pharmaceutical use of fused 1,2,4-triazoles |
| 05/18/2006 | US20060105987 Sulfur-containing phospholipid derivatives |
| 05/18/2006 | US20060105957 Loop peptide and TGFalpha for stimulating stem cell proliferation and migration |
| 05/18/2006 | US20060105938 Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein |
| 05/18/2006 | US20060105446 Biodegradable, resistant to nitrate salt, hardly forms spores, does not contain any plasmids; food and beverage additive; cosmetics |
| 05/18/2006 | US20060105386 17867, a novel human aminopeptidase |
| 05/18/2006 | DE10349979B4 Medikamentöse gezielte lokale Lipolyse Drug targeted local lipolysis |
| 05/18/2006 | DE102004054603A1 New D-xylopyranosyl-substituted phenyl compounds are sodium-dependent glucose cotransporter inhibitors useful to prevent or treat e.g. diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis |
| 05/18/2006 | CA2588087A1 Methods of reducing body fat |
| 05/18/2006 | CA2586946A1 Nutrition containing fat blend |
| 05/18/2006 | CA2586771A1 Stable formulations of insulinoptropic peptides |
| 05/18/2006 | CA2586761A1 Methods of treating diabetes mellitus |
| 05/18/2006 | CA2586623A1 Process for preparing quinoline compounds and products obtained therefrom |
| 05/18/2006 | CA2586479A1 Lipase inhibitors |
| 05/18/2006 | CA2586446A1 Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof |
| 05/18/2006 | CA2586068A1 Dibenzosuberone derivatives |
| 05/18/2006 | CA2585442A1 Protein hydrolysate with antidiabetic effect |
| 05/18/2006 | CA2584806A1 Treatment of obesity and related disorders |
| 05/18/2006 | CA2584225A1 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
| 05/17/2006 | EP1657954A1 Transmitter of wireless microphone, receiver for wireless microphone, mobile information communication apparatus, and communication system for wireless microphone |
| 05/17/2006 | EP1657311A1 Method of evaluating compound efficacious in treating obesity |
| 05/17/2006 | EP1657255A1 Novel protein and method for producing the protein |
| 05/17/2006 | EP1657252A2 PGC-1, a novel brown fat PPAR gamma coactivator |
| 05/17/2006 | EP1657244A1 2-thiaquinolizidines as glycosidase and glycosyltransferase inhibitors |
| 05/17/2006 | EP1657242A1 Imidazopyridine derivatives |
| 05/17/2006 | EP1656943A1 Extract from plant of japanese parsley family and process for producing the same |
| 05/17/2006 | EP1656941A1 Compositions for the treatment of diabetic nephropathy |
| 05/17/2006 | EP1656936A1 Macrophage activation inhibitor |
| 05/17/2006 | EP1656934A1 Use of physiologically active fatty acids for treating lipodystrophy |
| 05/17/2006 | EP1656839A1 Nutrition containing lipid blend |
| 05/17/2006 | EP1656838A1 Food for testing life style-related diseases |
| 05/17/2006 | EP1656368A2 Substituted hertocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 05/17/2006 | EP1656352A1 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO d AZEPINE AS A 5-HT sb 2c /sb RECEPTOR AGONIST |
| 05/17/2006 | EP1656148A1 Micronutrient supplement |
| 05/17/2006 | EP1656139A1 Aryl dicarboxamides |
| 05/17/2006 | EP1656136A1 Heterocyclic amide derivatives which possess glycogen phosphorylase inhibitory activity |
| 05/17/2006 | EP1656134A1 Indoline-sulfanilic acid amides used as ppar delta modulators |
| 05/17/2006 | EP1558252A4 Substituted furo 2,3-b| pyridine derivatives |
| 05/17/2006 | EP1506228A4 Role of p62 in aging-related disease |
| 05/17/2006 | EP1362047B1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 05/17/2006 | EP1345929B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345927B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345926B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1345925B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1317452B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1317447B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/17/2006 | EP1274711B1 New aza-indolyl derivatives |
| 05/17/2006 | EP1265616B1 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate |
| 05/17/2006 | EP1240518A4 Markers for identification and isolation of pancreatic islet alpha and beta cell progenitors |
| 05/17/2006 | EP1214409B1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 05/17/2006 | EP1204652B1 Novel succinate derivative compounds useful as cysteine protease inhibitors |
| 05/17/2006 | EP1135411B1 Methods and compositions for treating disorders involving excitotoxicity |
| 05/17/2006 | EP0975668B1 MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA |
| 05/17/2006 | EP0937077B1 Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
| 05/17/2006 | CN1774444A Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders |
| 05/17/2006 | CN1774433A Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists |
| 05/17/2006 | CN1774429A Medicinal composition |
| 05/17/2006 | CN1774420A Process for the preparation of N-substituted 2-cyanopyrrolidines |
| 05/17/2006 | CN1774418A Substituted N-arylheterocycles, method for production and use thereof as medicaments |
| 05/17/2006 | CN1774251A Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
| 05/17/2006 | CN1774244A Compounds for the treatment of metabolic disorders |
| 05/17/2006 | CN1774178A Pet food composition for regulating body weight and preventing obesity and related disorders in pets |
| 05/17/2006 | CN1772767A Prepn process and application of Chinese yam starch |
| 05/17/2006 | CN1772761A Serial cyclovirobuxine compounds as new medicine for preventing and treating cardiac vascular diseases and their prepn |
| 05/17/2006 | CN1772733A Cyanopyrrolidine derivatives |
| 05/17/2006 | CN1772721A Bromophenol compound and its prepn and application |
| 05/17/2006 | CN1772225A Recipe and prepn process of hypoglycemic Chinese medicine |
| 05/17/2006 | CN1772216A Solid mixture containing alpha-amylase and its prepn process and application in pharmaceutical industry |
| 05/17/2006 | CN1772215A Prepn process of micron hypoglycemic stomach benefiting health medicine granule, capsule and tablet |
| 05/17/2006 | CN1772208A Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia |
| 05/17/2006 | CN1772198A Prepn process of micron Yin-nourishing hypoglycemic milk |
| 05/17/2006 | CN1772197A Prepn process of micron Yin-nourishing hypoglycemic medicine granule, capsule and tablet |
| 05/17/2006 | CN1772193A Diabetes treating Chinese medicine |
| 05/17/2006 | CN1772183A Diabetes treating Chinese medicine |
| 05/17/2006 | CN1772178A Diabetes treating medicine |
| 05/17/2006 | CN1772170A Glabrous greenbrier total saponin extract and its prepn and use |
| 05/17/2006 | CN1772121A Wild camellia seed oil soft capsule |
| 05/17/2006 | CN1772110A Chinese medicine composition |
| 05/17/2006 | CN1772068A Fat eliminating morning and evening tea |
| 05/17/2006 | CN1772065A Chinese rose total flavone and its prepn and use |
| 05/17/2006 | CN1772055A Hyperlipemia treating Chinese medicine prepn and its prepn process |